BLFS — BioLife Solutions, Inc.

Summary of BioLife Solutions, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2025 Revenue: $24.8 million, up 20% year-over-year.
• Full-Year 2025 Revenue: $96.2 million, an increase of 29% from 2024.
• Adjusted Gross Margin: Q4 at 64% (down from 67% in Q4 2024); Full-year at 66% (down from 69% in 2024).
• Adjusted EBITDA: Q4 at $6.9 million (28% of revenue), compared to $3.7 million (18% of revenue) in Q4 2024; Full-year at $25.0 million (26% of revenue), up from $13.3 million (18%).
• Net Income: Adjusted net income of $1.9 million in Q4, compared to a net loss of $0.1 million in Q4 2024; Full-year adjusted net income of $6.3 million vs. a loss of $2.9 million in 2024.
• Cash and Marketable Securities: $120.2 million at year-end, up from $105.4 million at the end of 2024.

2. Strategic Updates and Business Highlights:

• Portfolio Optimization: Successful divestiture of the EVO product line, resulting in a streamlined focus on biopreservation media (BPM) and cell processing tools.
• Market Position: BPM products are embedded in 16 approved therapies and over 250 commercially sponsored CGT trials in the U.S., holding a 70% market share.
• Cross-Selling Initiatives: Efforts to increase revenue per patient dose by integrating additional products into existing customer workflows, with ongoing product evaluations.
• New Partnership: Entered a strategic agreement with Qkine Limited for exclusive distribution of certain cytokine products, enhancing the product offering and expanding market reach.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $112 million and $115 million, reflecting growth of 17% to 20%.
• Profitability Expectations: Anticipates achieving full-year GAAP net income for the first time in years, with continued expansion of adjusted EBITDA margins.
• Gross Margin Projections: Expected to remain in the mid-60s, similar to 2025, due to product mix changes.

4. Bad News, Challenges, or Points of Concern:

• Declining Gross Margins: Year-over-year declines attributed to product mix shifts and lower bag yields, which are a priority for improvement in 2026.
• Bag Yield Issues: Estimated to have caused a 2-3% headwind on gross margins in the second half of 2025, with a resolution expected in late 2026 after inventory adjustments.
• Market Dynamics: Although there is optimism regarding CAR-T therapies, the impact of recent regulatory changes (REMS removal) on revenue is still uncertain.

5. Notable Q&A Insights:

• Commercial vs. Clinical Growth: The CEO indicated that commercial customer revenue is expected to continue driving growth, with a projected increase in commercial mix to 50-55% in 2026.
• Bag Yield Improvement Timeline: Solutions for bag yield issues require a 90-day customer notification period and will take time to see benefits in revenue.
• Cytokine Partnership Potential: The Qkine collaboration is seen as a long-term strategic move rather than an immediate revenue driver, with expectations for revenue contributions starting late 2026.

Overall, BioLife Solutions, Inc. reported strong growth in 2025, with positive momentum heading into 2026, despite challenges related to gross margins and product yield issues. The company remains focused on strategic initiatives to enhance its market position and drive profitability.